<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article39</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/EAST-AFNET_4" style="display:block; margin-bottom:10px;">EAST-AFNET 4 Original</a></li>
<h2><strong>EAST-AFNET 4</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Early Rhythm-Control Therapy in Patients with Atrial Fibrillation". The New England Journal of Medicine. Published on August 29, 2020. Updated on October 13, 2020.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does early rhythm-control therapy improve outcomes over usual care in patients with early atrial fibrillation (AF) and cardiovascular (CV) conditions?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Early rhythm-control therapy in patients with atrial fibrillation diagnosed ≤1 year before and with cardiovascular conditions reduced the risk of adverse cardiovascular outcomes compared to usual care, without significantly affecting the number of nights spent in the hospital.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Modern guidelines do not specify the timing of rhythm vs. rate control initiation in the management of AF patients.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- International, investigator-initiated, parallel-group, randomized, open, blinded-outcome-assessment trial<br/>
- N=2,789 patients with recent AF (median time since diagnosis, 36 days) and CV conditions<br/>
- Interventions: Early rhythm control vs. usual care<br/>
- Setting: 135 centers across 11 European countries<br/>
- Enrollment: 2011-2016<br/>
- Follow-up: Median 5.1 years per patient<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcomes: Death from CV causes, stroke, hospitalization for worsening heart failure or acute coronary syndrome. Secondary outcomes included the number of nights in the hospital per year.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Adults (≥18 years) with AF diagnosed ≤12 months before enrollment<br/>
- Patients also had either age &gt;75 years, prior transient ischemic attack or stroke, or two additional risk factors (e.g., age &gt;65 years, female sex, CHF, etc.)<br/>
<br/>
Exclusion Criteria:<br/>
- Not specified in the summary<br/>
<br/>
Baseline Characteristics:<br/>
- Mean age: 70 years, 46% female, median time since AF diagnosis 36 days<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Early rhythm control: Treatment with antiarrhythmic drugs or AF ablation; cardioversion for persistent AF initiated after randomization<br/>
- Usual care: Rate-control therapy; rhythm control for AF-related symptom management<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- First primary outcome event occurred less frequently in early rhythm control than usual care (hazard ratio, 0.79; 96% CI, 0.66 to 0.94; P=0.005)<br/>
- The number of nights in the hospital was not significantly different (P=0.23)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Open trial design, which may introduce bias despite blinded outcome assessment<br/>
- Not designed to assess specific components of rhythm-control therapy<br/>
- Results may not generalize to patients with later initiation of rhythm-control therapy<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by various institutions including the German Ministry of Education and Research, German Center for Cardiovascular Research, and European Heart Rhythm Association, among others.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Kirchhof, P., Camm, A.J., Goette, A., et al. 2020. "Early Rhythm-Control Therapy in Patients with Atrial Fibrillation." NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
